{"id":"https://openalex.org/G2141568614","display_name":"Does treatment with the GLP-1 receptor agonist semaglutide reduce alcohol intake in patients with alcohol use disorder and comorbid obesity?","description":null,"funder_award_id":"nnf-grant-86f16dd91e63956b","funder":{"id":"https://openalex.org/F4320325957","display_name":"Novo Nordisk Fonden","doi":"https://doi.org/10.13039/501100009708"},"funded_outputs":[],"funded_outputs_count":0,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":5465567.0,"currency":"DKK","amount_usd":832432.52,"amount_usd_basis":"daily_rate","recipients":[],"recipient_countries":[],"recipient_regions":[],"research_scope":{"is_research":null,"basis":"unknown","tier":null},"funding_type":"research","funder_scheme":null,"start_date":"2022-01-01","end_date":null,"start_year":2022,"end_year":null,"landing_page_url":null,"doi":null,"provenance":"novo_nordisk_fonden_grants","lead_investigator":{"given_name":"Anders","family_name":"Fink-Jensen","orcid":null,"role_start":"2022-01-01","affiliation":{"name":"Psykiatrisk Center K\u00f8benhavn","country":null,"ids":null},"author":null,"institutions":null},"co_lead_investigator":null,"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G2141568614","primary_topic":{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9404,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.9404,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.0275,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0178,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.999},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.964},{"id":"https://openalex.org/keywords/alcoholism","display_name":"alcoholism","score":0.989},{"id":"https://openalex.org/keywords/alcohol-consumption","display_name":"alcohol consumption","score":0.764},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.786},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.819},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.515}],"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"institution_awarded":[],"updated_date":"2026-11-13T03:01:57.000Z","created_date":"2026-07-13T04:53:30.000Z"}
